援ш컯�렪�룊�꽭�룷�븫醫낆뿉�꽌 DNA hypermethylation�뿉 �쓽�븳 glutathione peroxidase 3 諛쒗쁽�쓽 �엫�긽蹂묐━�븰�쟻 �쓽�쓽 by �젙�옱�듅
  
저작자표시-비영리-변경금지 2.0 대한민국 
이용자는 아래의 조건을 따르는 경우에 한하여 자유롭게 
l 이 저작물을 복제, 배포, 전송, 전시, 공연 및 방송할 수 있습니다.  
다음과 같은 조건을 따라야 합니다: 
l 귀하는, 이 저작물의 재이용이나 배포의 경우, 이 저작물에 적용된 이용허락조건
을 명확하게 나타내어야 합니다.  
l 저작권자로부터 별도의 허가를 받으면 이러한 조건들은 적용되지 않습니다.  
저작권법에 따른 이용자의 권리는 위의 내용에 의하여 영향을 받지 않습니다. 
이것은 이용허락규약(Legal Code)을 이해하기 쉽게 요약한 것입니다.  
Disclaimer  
  
  
저작자표시. 귀하는 원저작자를 표시하여야 합니다. 
비영리. 귀하는 이 저작물을 영리 목적으로 이용할 수 없습니다. 
변경금지. 귀하는 이 저작물을 개작, 변형 또는 가공할 수 없습니다. 
Clinicopathological implications of glutathione peroxidase 
3 downregulation through DNA hypermethylation in oral 
squamous cell carcinoma
Jae-Seung Chung
The Graduate School
Yonsei University
Department of Dentistry
Clinicopathological implications of glutathione peroxidase 
3 downregulation through DNA hypermethylation in oral 
squamous cell carcinoma
Directed by Professor In Ho Cha
A Doctoral Dissertation
Submitted to the Department of Dentistry
and the Graduate School of Yonsei University
in partial fulfillment of the requirements for the degree of
Ph.D. in Dental Science
Jae-Seung Chung
December 2016
This certifies that the Doctoral Dissertation
of Jae-Seung Chung is approved.
Thesis Supervisor: Prof. In-Ho Cha
Jin Kim
Hyung Jun Kim
                      
Nam Woong
Xianglan Zhang
The Graduate School
Yonsei University
December 2016
감사의 글
연세대학교 치과대학을 졸업한지 20년이 되었습니다. 대학원에 진학하여 학문
에 대한 열정을 키웠고 이 논문에 그 동안의 고민과 정성을 담아 보았습니다. 
먼저 대학원에 진학할 수 있도록 용기와 힘을 불어넣어 주신 차인호 지도 교
수님께 깊은 감사를 올립니다. 또한 연구기간 동안 열정적인 모습으로 연구를
진행하며 아낌없는 도움을 주신 장향란 교수님께도 많은 감사를 드립니다. 공
개 발표 때 아낌없는 조언으로 도와주셨던 김형준 교수님께도 깊은 감사를 드
립니다. 논문심사과정에서 바쁜 시간을 쪼개어 논문의 방향과 틀을 잡아주신
김 진 교수님, 남 웅 교수님께도 감사를 드립니다. 학위논문을 준비하는 동안
학문적 발전을 포함한 제 자신의 발전을 위해 많은 노력을 했고 힘들 때 마다
때로는 따뜻하게 때로는 호된 질책으로 저를 바로 잡아 주셨던 차인호 지도교
수님의 깊은 뜻을 조금이나마 느낄 수 있는 시간들이었습니다. 앞으로 환자를
진료하는 의사로서 학문에 대한 발전을 게을리 하지 않는 진정한 의료인이 되
도록 노력하겠습니다. 마지막으로 저를 낳아주시고 길러주신 아버님, 어머님,
그리고 멀리서 늘 격려해주시는 장인, 장모님, 그리고 늘 마음속으로 저를 믿
고 평생을 함께하는 사랑하는 아내와 사랑하는 두 딸 정지안, 정다안 에게 깊
은 감사를 전합니다.
2016년 12월 정 재 승
iTABLE OF CONTENTS
TABLE OF CONTENTS··············································································i
LIST OF FIGURES ·················································································· iii
ABSTRACT (IN ENGLISH) ······································································ iv
I. INTRODUCTION ·················································································· 1
II. MATERIALS AND METHODS································································· 5
1. Patients and samples·············································································· 5
2. Immunohistochemistry ··········································································· 7
3. Cell lines and cell culture········································································· 8
4. Immunocytochemistry············································································ 8
5. Total RNA extraction and reverse transcription PCR analysis ································· 9
6. Treatment with 5-aza-2’-deoxycytidine (5-Aza) ··············································· 9
7. DNA extraction and methylation-specific PCR ················································· 9
8. Statistical analysis ···············································································10
III. RESULTS··························································································11
ii
1. GPX3 mRNA expression in OSCC cell lines ··················································11
2. GPX3 protein expression in OSCC cell lines ··················································12
3. Promoter hypermethylation of GPX3 in OSCC cell lines ·····································13
4. Restoration of GPX3 expression by 5-Aza treatment in OSCC cell lines ····················14
5. Promoter hypermethylation of GPX3 in OSCC tissue samples ·······························16
6. GPX3 protein expression in normal oral mucosa and OSCC tissues··························18
7. Clinicopathological significance of GPX3 expression in 198 patients with OSCC ··········21
8. Survival analysis according to GPX3 expression in patients with OSCC·····················23
IV. DISCUSSION···················································································· 24
V. CONCLUSION ··················································································· 27
VI. REFERENCES ·················································································· 28
ABSTRACT (IN KOREAN)······································································· 34
iii
LIST OF FIGURES
Figure 1. GPX3 mRNA expression in 5 OSCC cell lines······································11
Figure 2. GPX3 expression in normal keratinocyte and OSCC cell lines ·················· 12
Figure 3. MSP analysis in OSCC cell lines ····················································· 13
Figure 4. GPX3 expression was restored after 5-Aza treatment at both mRNA and protein 
levels in OSCC cell lines······························································· 14
Figure 5. MSP analysis in normal oral mucosa and OSCC tissue samples with or without 
GPX3 expression········································································ 17
Figure 6. GPX3 expression in normal oral mucosa and OSCC tissues ····················· 19
Figure 7. Frequency of GPX3 expression in normal oral mucosa and OSCC tissues ···· 20
Figure 8. Overall survival analysis in 198 patients with OSCC ····························· 23
iv
ABSTRACT
Clinicopathological implications of glutathione peroxidase 
3 downregulation through DNA hypermethylation in oral 
squamous cell carcinoma
Jae-Seung Chung
Department of Dentistry
The Graduate School, Yonsei University
(Directed by Professor In Ho Cha, D.D.S., Ph.D.)
Reactive oxygen species (ROS) have been shown to be involved in tumor initiation and 
progression via structural changes in cancer-related genes. Glutathione peroxidase 3 
(GPX3), a member of the glutathione peroxidase family, is a major scavenger of ROS 
produced by normal metabolism or after oxidative damage to host cells. A possible tumor 
suppressor function of GPX3 and its downregulation caused by promotor 
hypermethylation have been investigated in various cancers. 
vIn this study, we investigated the association between methylation status and GPX3 
expression in oral squamous cell carcinoma (OSCC) and further investigated the 
clinicopathological significance of GPX3 expression in patients with OSCC who 
underwent long-term follow-up.
Promoter hypermethylation of GPX3 was frequently detected in both OSCC cell lines 
(100%) and tissue samples (75%). In contrast, only 33.3% of normal oral mucosa samples
showed hypermethylation of GPX3. In OSCC cell lines, GPX3 expression was restored 
after 5-aza-2’-deoxycytidine treatment at both the mRNA and protein levels. GPX3 
protein expression was significantly decreased in OSCC tissues (56.1%) compared to
normal oral mucosa (100%). In patients with OSCC, GPX3 downregulation was 
significantly associated with histological grade (P=0.005), lymph node metastasis 
(P=0.001), vascular invasion (P=0.016), and poor prognosis (P=0.007). We concluded 
that promoter hypermethylation-induced GPX3 downregulation is significantly related to 
poor prognostic indicators and decreased overall survival in OSCC, and these findings 
provide further evidence for GPX3 as a novel diagnostic and prognostic biomarker in 
patients with OSCC. 
Key words: GPX3 downregulation, promoter hypermethylation, molecular biomarker, 
OSCC
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I. INTRODUTION
Reactive oxygen species (ROS) are highly reactive, oxygen-containing chemical species, 
including free radicals(Cheeseman and Slater, 1993). ROS can be generated by 
endogenous and exogenous substances, and have a dual nature. ROS are necessary for the 
2normal physiologic functions of cells; however, excessive generation of ROS can induce 
various types of cellular damage. Moreover, excessive production of ROS has been 
shown to be involved in tumor initiation and progression via structural changes in cancer-
related genes(Katakwar, et al., 2016).
In normal physiologic conditions, cells avoid ROS-induced damage by balancing the 
elimination and generation of ROS using a scavenging system. Non-enzymatic chemicals 
and enzymatic systems are involved in the ROS scavenging system. The glutathione 
peroxidase (GPX) family is the major enzymatic system of ROS scavenging, and these 
enzymes are widely distributed in various organs(Takebe, et al., 2002). GPX3, a secreted 
GPX enzyme, is detectable in plasma, thyroid colloid, and mucosal surfaces, and is also 
selectively expressed in various normal human tissues such as the gastrointestinal tract, 
epithelial cells of the oviducts, and the cervix(He, et al., 2011; Kohrle, 2005; Lapointe, et 
al., 2005; Schomburg and Kohrle, 2008; Zhang, et al., 2014). As one of the key 
antioxidative enzymes, GPX3 catalyzes the reduction of lipid peroxides and hydrogen 
peroxide. Hydrogen peroxide can regulate multiple biological characteristics of cancer 
cells such as proliferation, migration, invasion, angiogenesis, and apoptosis, and GPX3 is 
expected to have implications for malignant transformation and cancer progression via 
control of the hydroperoxide levels of the cells(El Haddad, et al., 2012). Some 
investigators have shown that the production of ROS increased after GPX3 silencing in 
both colon cancer cell lines and muscle stem cells(Barrett, et al., 2013; Mork, et al., 
1998).
3Recently, the role of GPX3 expression in cancer initiation and progression has been 
documented in various human cancers(Brigelius-Flohe and Kipp, 2009; He, et al., 2011; 
Yu, et al., 2007). Downregulation of GPX3 in melanoma cell lines can increase the 
invasive ability and motility of the cells(Saga, et al., 2008). Moreover, in prostate cancer, 
GPX3 overexpression can attenuate tumorigenic and metastatic activity both in vitro and 
in vivo(Brigelius-Flohe and Kipp, 2009). Loss of GPX3 expression is significantly 
associated with poor prognosis in various cancers including gallbladder cancer, cervical 
cancer, multiple myeloma, gastric cancer, and melanoma(Chen, et al., 2016; Saga, et al., 
2008; Yang, et al., 2013; Zhang, et al., 2010; Zhang, et al., 2014). GPX3 may function as 
a tumor suppressor in cancer progression. The tumor suppressor activity of GPX3 seems 
to relate to its ability to suppress the expression of c-met. 
The mechanisms of regulation of GPX3 expression remain largely unknown. Oxidative 
stress can lead to transcriptional upregulation of GPX3 in patients with asthma, 
inflammatory bowel disease, and experimental colitis, as well as in the diabetic mouse 
heart(Comhair, et al., 2001; Hoffenberg, et al., 1997; Kaiser, et al., 2013; Ma, et al., 
2003). However, GPX3 expression is usually downregulated by promoter 
hypermethylation in various cancers such as melanoma and cervical, gastric, and 
esophageal cancers(He, et al., 2011; Saga, et al., 2008; Tham, et al., 2002; Zhang, et al., 
2014). Promoter hypermethylation resulting in consequent downregulation or silencing of 
tumor suppressor genes is a hallmark of human cancers and an essential part of malignant 
transformation and cancer progression(Iwata, et al., 2006; Peng, et al., 2012). Inactivation 
4of GPX3 via monoallelic hypermethylation has been found in benign precursor lesions of 
the esophagus, and inactivation by hypermethylation of both alleles has been detected in 
invasive carcinoma(Herman and Baylin, 2003). Promoter methylation may be a crucial 
cause of GPX3 downregulation in both precancerous lesions and cancers.
Oral cancer is the ninth most common cause of cancer-related death worldwide, with 
529,000 new cases diagnosed globally in 2012, and 29,200 deaths(Thompson, 2014).
Oral squamous cell carcinoma(OSCC) is the most common histological type of oral 
cancer. In the present study, we determined GPX3 expression and promoter 
hypermethylation in primary OSCC cell lines and tissues, and further investigated the 
clinicopathological significance of GPX3 expression in patients with OSCC. 
5II. MATRIALS AND METHODS
1. Patients and samples
This study included OSCC tissue samples obtained from 198 patients with OSCC who 
received surgical treatment at Yonsei University Hospital, Korea, between 1995 and 2010. 
The following clinical parameters were recorded: age, gender, lesion site, T stage, LN 
metastasis, histological grade, perineural invasion, and vascular invasion (Table 1).
Follow-up for the cohort of patients was performed for at least 5 years. The study was 
approved by the Institutional Review Board of the Dental Hospital, Yonsei University 
Medical Center (IRB No.2-2011-0044).
6Table 1. Clinicopathological characteristics of 198 patients with OSCC 
Clinicopathological variables No. of patients (%)
Total cases 198
Age, years
Median age (range) 60(26-86)
  ≤60 100(50.5)
  >60 98(49.5)
Gender
  Male 144(72.7)
  Female 54(27.3)
Site
  Tongue 47(23.7)
  Floor of mouth 9(4.5)
  Retromolar trigone 26(13.1)
  Gingiva 90(45.5)
  Palate 2(1.0)
  Lip 1(0.5)
  Cheek 23(11.6)
T stage
  T1 24(12.1)
  T2 56(28.3)
  T3 14(7.1)
  T4 104(52.5)
N stage
  N0 122(61.6)
  N1 28(14.1)
  N2 46(23.2)
  N3 2(1.0)
Histologic grade*
  WD 50(25.3)
  MD 115(58.1)
  PD 33(16.7)
Perineural invasion
  Negative 173(87.4)
  Positive 25(12.6)
Vascular invasion
  Negative 178(89.9)
  Positive 20(10.1)
*WD: well differentiated; MD: moderately differentiated; PD: poorly differentiated
72. Immunohistochemistry
Formalin-fixed, paraffin-embedded archival OSCC tissue sections were used for 
immunohistochemistry. Mouse monoclonal antibody against GPX3 (1:200; Abcam, 
Cambridge, MA, USA) was used as the primary antibody for the staining. All sections 
were deparaffinized with xylene and rehydrated with graded alcohol. Following antigen 
retrieval with antigen retrieval buffer (Dako, Carpinteria, CA, USA), endogenous 
peroxidase activity was blocked with endogenous enzyme block solution (Dako). The 
sections were incubated with primary antibody at room temperature for 1h. Real 
EnvisionTM HRP Rabbit/Mouse detection system (Dako) was used as the secondary 
antibody. Slides were visualized with 3,3’-diaminobenzidine (DAB) and then 
counterstained with hematoxylin. Staining of normal mouse kidney tissue samples was 
run in parallel as a positive control. For a negative control, the primary antibody was 
replaced by phosphate buffered saline. The scoring of protein expression was performed 
using the weighted histoscore method, as described previously.(Witton, et al., 2004) The 
intensity of tumor cell staining was scored as 0 (negative), 1 (light brown), 2 (brown), and 
3 (dark brown). The final score was calculated as follows: total score = (0x percentage of 
negative cells) + (1x percentage of light brown staining cells) + (2x percentage of brown 
staining cells) + (3x percentage of dark brown staining cells). Patients were subdivided 
into two groups based on the total score: low (total score 0–100) and high (total score 
101–300) expression groups.
83. Cell lines and cell culture
OSCC cell lines HSC-2, HSC-3 and CA9-22 were supplied by the Korean Cell Line Bank 
(Seoul, Korea), and YD-10B and YD-38 were previously established by the Oral Cancer 
Research Institute, Yonsei University, Korea.(E. J. Lee, et al., 2005) All OSCC cell lines 
were cultured in mixed medium that contained Dulbecco’s Modified Eagle’s medium 
(DMEM; Gibco BRL, Grand Island, NY, USA) and Ham’s nutrient mixture F12 (Gibco 
BRL) medium (3:1 ratio) and maintained in a cell culture incubator (5% CO2) at 37°C. 
The supplement consisted of 10% fetal bovine serum (FBS; HyClone Laboratories, Inc., 
Logan, UT, USA), 100 U/mL of penicillin, 100 mg/mL streptomycin, 1x10-10M cholera 
toxin, 0.4 g/mL hydrocortisone, 5 µg/mL insulin, 5 µg/mL transferrin, and 2x10-11M 
triiodothyronine. 
4. Immunocytochemistry in human OSCC cell lines
GPX3 protein expression was detected in OSCC cell lines by immunocytochemistry. Cell 
lines were cultured on glass coverslips containing 6-well plates. The cells were fixed with 
95% ethanol before blocking with 5% bovine serum antigen at room temperature for 1h. 
After blocking of the endogenous peroxidase activity, the cells were incubated with 
primary antibody at room temperature for 1h. Real EnvisionTM HRP Rabbit/Mouse 
detection system (Dako) was used as the secondary antibody. Visualization was 
conducted with DAB and counterstaining was performed with hematoxylin. 
95. Total RNA extraction and reverse transcription PCR analysis
Total RNA was purified from OSCC cell lines using TRIzol reagent (Invitrogen, Carlsbad, 
CA, USA). After cDNA synthesis, conventional RT-PCR analysis was performed using 
AccuPower PCR PreMix (Bioneer Corp., Seoul, Korea) with an annealing temperature of 
58°C. β-actin was used as the housekeeping gene. Oligonucleotide primers used for the PCR
were: 5'-CAACCAATTTGGAAAACAGG-3' and 5'-GTGGGAGGACAGGAGTTCTT-3' 
for GPX3; and 5'-ATAGCACAGCCTGGATAGCAACGTAC-3' and 5'-
CACCTTCTACAATGAGCTGCGTGTG-3' for β-actin. (Zhang, et al., 2014)
6. Treatment with 5-aza-2’-deoxycytidine (5-Aza)
OSCC cell lines (HSC-3, YD-10B, and YD-38) were treated with 5-Aza (Sigma-Aldrich, 
Inc., St. Louis, MO, USA), 10 µM, for 72h, with drug replacement every 24h. GPX3 
mRNA and protein expression were detected in each group of cells by RT-PCR analysis 
and immunocytochemistry. 
7. DNA extraction and methylation-specific PCR
Genomic DNA was extracted from 5 OSCC cell lines, 6 normal oral mucosa tissue samples, 
and 12 OSCC tissue samples using the QIAamp DNA mini kit (Qiagen GmbH, Hilden, 
Germany). Modification of DNA was performed using the EZ DNA Methylation kit (Zymo 
Research Corp., Irvine, CA, USA). The primers 5'-TATGTTATTGTCGTTTCGGGAC-3'
10
and 5'-GTCCGTCTAAAATATCCGACG-3' were used in methylation-specific 
amplification, and the primers 5'-TTTATGTTATTGTTTTGGGATG-3' and 5'-
ATCCATCTAAAATATCCAACACTCC-3' were used in unmethylation-specific 
amplification. The annealing temperature of the PCR was 59°C. 
8. Statistical analysis
The statistical analysis was performed using commercially available software (SPSS 
version 23.0; IBM Corp., Armonk, NY, USA) for statistical analysis. A value of P<0.05 
was considered to indicate a statistically significant difference. The difference between 
GPX3 mRNA expression in normal oral mucosa and OSCC tissue samples was 
investigated with the Mann-Whitney U test. The chi-square test and Fisher’s exact test 
were used to analyze the differences between groups of clinical samples. Survival 
analysis for patients with OSCC was performed with Kaplan-Meier analysis, and the 
differences were compared with the log-rank test. 
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III. RESULTS
GPX3 mRNA expression in OSCC cell lines
GPX3 mRNA expression was determined in 5 OSCC cell lines by RT-PCR analysis. In 
this study, GPX3 mRNA expression was observed in CA9-22 and HSC-2, but not in 
HSC-3, YD-10B, and YD-38 cell lines. Normal keratinocytes obtained from foreskin 
were used as a positive control (Figure 1).  
Figure 1. GPX3 mRNA expression was detected by RT-PCR analysis in 5 OSCC cell 
lines. Down-regulation of GPX3 expression was found in HSC-3, YD-10B and YD-38 
cell lines.
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GPX3 protein expression in OSCC cell lines
GPX3 protein expression was determined in 5 OSCC cell lines by immunocytochemistry. 
GPX3 protein expression was found in HSC-2 and CA9-22, but not in HSC-3, YD-10B 
and YD-38 cell lines, in the present study. Normal keratinocytes obtained from foreskin 
were used as a positive control (Figure 2).  
Figure 2. GPX3 protein expression in normal keratinocytes and OSCC cell lines. Down-
regulation of GPX3 protein expression was found in HSC-3, YD-10B, and YD-38 cell 
lines. The original magnification of all figures was ×200. (Scale bar of all figures, 100
μm).
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Promoter hypermethylation of GPX3 in OSCC cell lines
Promoter hypermethylation of GPX3 was determined in 5 OSCC cell lines. Methylation-
specific amplification of GPX3 was found in all of the OSCC cell lines. Full methylation 
(presence of only methylated CpGs) was found in HSC-3, YD-10B, and YD-38, which 
showed negative GPX3 expression at both the mRNA and protein levels. Meanwhile, 
partial methylation (presence of both methylated and unmethylated CpGs) was found in 
both CA9-22 and HSC-2, which showed GPX3 expression at both the mRNA and protein 
levels. CpGnome Universal Methylated DNA (Chemicon International, Inc., Temecula, 
CA, USA) was used as the positive control (Figure 3).
Figure 3. MSP analysis in OSCC cell lines. Methylation-specific amplification of GPX3 
was found in all of the cell lines. Full methylation was found in HSC-3, YD-10B, and 
YD-38 cell lines, whereas CA9-22 and HSC-2 cell lines showed partial methylation of
GPX3. 
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Restoration of GPX3 expression by 5-Aza treatment in OSCC cell lines
To investigate whether promoter hypermethylation of GPX3 can influence repression of 
GPX3 expression, 3 OSCC cell lines which showed full methylation for GPX3 were 
treated with 5-Aza, a demethylation agent. The results showed that both mRNA and 
protein expression of GPX3 were restored after 5-Aza treatment (Figure 4 A-B).
(A)
Figure 4A. GPX3 mRNA expression was detected in OSCC cell lines with or without 5-
Aza treatment by RT-PCR analysis. GPX3 mRNA expression was restored after 5-Aza 
treatment in all 3 OSCC cell lines showed full methylation for GPX3.
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(B)
Figure 4B. GPX3 protein expression was detected in OSCC cell lines with or without 5-
Aza treatment by immunocytochemistry. GPX3 protein expression was restored after 5-
Aza treatment in all 3 OSCC cell lines showed full methylation for GPX3. (Original 
magnification: ×200; Scale: 100 μm).
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Promoter hypermethylation of GPX3 in OSCC tissue samples
Promoter hypermethylation of GPX3 was also detected in normal oral mucosa and human 
OSCC tissue samples with or without GPX3 expression. Six samples were randomly 
selected from each group for MSP analysis. Unmethylation-specific amplification was 
more frequently detected in normal oral mucosa and OSCC tissues with GPX3 expression 
than in OSCC tissues without GPX3 expression. Moreover, methylation-specific 
amplification was detected more often in OSCC tissues without GPX3 expression than in 
normal oral mucosa and OSCC tissues with GPX3 expression. Four (66.7%) of the 
normal oral mucosa samples showed unmethylation for GPX3, and partial methylation 
was found in 2 (33.3%) cases. OSCC tissues without GPX3 expression showed full 
methylation in 4 (66.7%) cases and partial methylation in 2 (33.3%) cases. In contrast, 
OSCC tissues with GPX3 expression showed unmethylation in 3 (50%) cases and partial 
methylation in 3 (50%) cases (Figure 5).
17
Figure 5. MSP analysis in 6 normal oral mucosa and OSCC tissue samples with (n=6) or 
without (n=6) GPX3 expression. Six samples were randomly selected from each group 
for MSP analysis.
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GPX3 protein expression in normal oral mucosa and OSCC tissues
GPX3 expression was detected in the cytoplasm of normal epithelial cells of normal oral 
mucosa (Figure 6A-B) and cancer cells of OSCC tissues (Figure 6D-F). Cytoplasmic 
expression of GPX3 was detected in all normal oral mucosa samples and was 
significantly decreased in OSCC tissue samples (56.1%) (P<0.001) (Figure 7A).
Moreover, high expression of GPX3 was also more frequently detected in normal oral 
mucosa tissues (83.3%) than in OSCC tissue samples (27.8%) in the present study
(Figure 7B) (P<0.001).
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Figure 6. Protein expression of GPX3 in normal oral mucosa (A-B) and OSCC tissues (C, 
F). GPX3 expression was typically found in cytoplasm of normal epithelial cells and 
cancer cells. Low (A) and high (B) levels of GPX3 expression in normal oral mucosa.
Negative (C), low (C, D), and high (F) GPX3 expression in OSCC tissues. (Original 
magnification, x200; scale bar, 100 μm).
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Figure 7. Frequency of GPX3 expression in normal oral mucosa and OSCC tissues. 
GPX3 expression was detected more often in normal oral mucosa than in OSCC tissues
(A). High level of GPX3 expression was more frequently detected in normal oral mucosa 
than in OSCC tissue samples (B). The results were analyzed using Fisher’s exact test 
(*P<0.001).  
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Clinicopathological significance of GPX3 expression in 198 patients 
with OSCC 
GPX3 expression was more frequently detected in patients without LN metastasis (65.6%) 
than in patients with LN metastasis (40.8%) (P<0.001). Moreover, patients with poorly 
differentiated OSCC showed decreased GPX3 expression (30.3%) compared to patients 
with well differentiated (60.0%) or moderately differentiated OSCC (61.7%) (P=0.005).
A high level of GPX3 expression was more frequently detected in patients without 
vascular invasion (30.3%) than in patients with vascular invasion (5.0%) (P=0.016) 
(Table 2).
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Table 2. Clinicopathological significance of GPX3 expression in 198 patients with OSCC 
Variables
GPX3
P
GPX3
P
Total Negative Positive Low High
T stage
  T1-T2 80 36(45.0) 44(55.0)
0.804
57(71.3) 23(28.7)
0.801
  T3-T4 118 51(43.2) 67(56.8) 86(72.9) 32(27.1)
N stage
  N0 122 42(34.4) 80(65.6)
0.001
79(64.8) 43(35.2)
0.003
  N1-3 76 45(59.2) 31(40.8) 64(84.2) 12(15.8)
Histologic grade
  WD 50 20(40.0) 30(60.0)
0.005#*
35(70.0) 15(30.0)
0.088  MD 115 44(38.3) 71(61.7) 79(68.7) 36(31.3)
  PD 33 23(69.7) 10(30.3) 29(87.9) 4(12.1)
Perineural invasion
  Negative 173 73(42.2) 100(57.8)
0.194
122(70.5) 51(29.5)
0.16
  Positive 25 14(56.0) 11(44.0) 21(84.0) 4(16.0)
Vascular invasion
  Negative 178 75(42.1) 103(57.9)
0.127
124(69.7) 54(30.3)
0.016
  Positive 20 12(60.0) 8(40.0) 19(95.0) 1(5.0)
WD: well differentiated; MD: moderately differentiated; PD: poorly differentiated;#The results 
were analyzed by chi-squre test. *Signifiicant differences were found between WD versus PD and 
MD versus PD in GPX3 expression. 
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Survival analysis according to GPX3 expression in patients with OSCC 
Survival analysis using the Kaplan-Meier method was performed to assess the prognostic 
significance of GPX3 expression in patients with OSCC. No significant difference in 
overall survival was found between patients with positive and negative GPX3 expression 
(Figure 8A). Patients with low expression of GPX3 showed poorer prognosis than 
patients with high expression of GPX3 (P=0.007, median survival duration 39.7 months 
for group with low GPX3 expression versus 51.1 months for group with high GPX3 
expression) (Figure 8B).
Figure 8. Overall survival analysis according to GPX3 expression in 198 patients with 
OSCC. The 198 patients with OSCC were classified into groups with negative 
(blue)/positive (green) (A) and low (blue) and high (green) GPX3 expression, and overall 
survival was analyzed by Kaplan-Meier analysis. 
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IV. DISCUSSION
DNA methylation, as one of the common physiologic epigenetic modulations, can 
regulate gene transcription(Baumgartel, et al., 2011; Deaton and Bird, 2011; Esteller, 
2008). Aberrant methylation of DNA CpG regions, which silence tumor suppressor genes 
via hypermethylation and/or activate oncogenes via hypomethylation, is involved in 
various biological behaviors of cells, such as cell cycle signaling, DNA repair, and 
apoptotic pathways, and thereby contributes to malignant transformation and cancer 
progression(Esteller, 2008; Gerhauser, 2013; Jaenisch and Bird, 2003; Radhakrishnan, et 
al., 2011; Zeilinger, et al., 2013). In addition to its biological implications for malignant 
conversion, aberrant methylation is a useful biomarker for early identification and clinical 
assessment of various human cancers(Mulero-Navarro and Esteller, 2008). It is essential 
to identify novel and cancer-specific aberrant methylated genes for both mechanistic and 
translational investigations of human cancer(Baylin, 2005).
Both genetic and epigenetic aberrations are involved in molecular pathogenesis of the 
multistep progression. Recently, epigenetic repression of various tumor suppressor 
genes, such as p16, was reported in oral cancers, implying that epigenetic silencing of 
tumor suppressor genes is a crucial molecular mechanism in oral cancer carcinogenesis 
and progression(Lopez, et al., 2003; Radhakrishnan, et al., 2011; von Zeidler, et al., 
2004).
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Similar to other cancers, we found that GPX3 expression was downregulated by promoter 
hypermethylation at both the mRNA and protein levels in OSCC cell lines, but not in 
normal keratinocytes. GPX3 promoter hypermethylation was more frequently detected in 
OSCC tissues than in normal oral mucosa. Concordant with these findings, GPX3 protein 
expression was more frequently detected in normal oral mucosa tissue samples than in 
OSCC tissues. All of these results implied that GPX3 repression was also induced by 
epigenetic silencing in OSCC. 
Interestingly, some normal oral mucosa samples also showed promoter methylation of 
GPX3 and demonstrated decreased GPX3 protein expression. Methylation patterns are 
related to environmental risk exposures such as tobacco, alcohol, and diet, in addition to 
an individual’s genetic profile(Verma, 2012). Hypermethylation of p16 has also been 
detected both in normal oral mucosa and saliva DNA of smokers. GPX3 downregulation 
may also occur in the initial stages of carcinogenesis even in the absence of
morphological changes. Some investigators have shown that methylation-induced GPX3 
repression is a consistent and progressive molecular mechanism in Barrett’s 
tumorigenesis. Compared to normal esophageal mucosa samples showing strong diffuse 
cytoplasmic expression for GPX3, both GPX3 promoter methylation and loss of GPX3 
protein expression were more frequently found in Barrett’s esophagus and dysplasia 
lesions, and became more so in esophageal adenocarcinoma lesions(O. J. Lee, et al., 
2005). In the present study, the frequency of loss of GPX3 expression was increased in 
OSCC compared to normal oral mucosa. Additionally, GPX3 expression was significantly 
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decreased in patients with OSCC with LN metastasis or vascular invasion. The prominent 
influence of GPX3 expression on decreased cancer cell motility and invasion ability was 
previously reported in melanoma(Chen, et al., 2016). Moreover, a significant association 
between GPX3 expression and LN metastasis was also reported in various cancers 
including gastric cancer, cervical cancer, and melanoma(Chen, et al., 2016; Peng, et al., 
2012; Zhang, et al., 2014). The prognostic significance of GPX3 methylation and protein 
expression has been investigated in various cancers, and GPX3 promoter methylation as 
well as loss of GPX3 expression are known as poor prognostic indicators(Chen, et al., 
2011; Chen, et al., 2016; Zhang, et al., 2014). Similar results were also found in OSCC, in 
the present study. We found that patients with low levels of GPX3 expression showed 
poor prognosis than patients with high levels of GPX3 expression. 
Our results showed that GPX3 downregulation was induced by promoter 
hypermethylation in OSCC, and this was significantly related to poor prognostic 
indicators and decreased overall survival of patients with OSCC. Our findings provide 
further evidence for GPX3 as a novel diagnostic and prognostic biomarker in OSCC. 
GPX3 may also serve as a possible therapeutic target for patients with OSCC. 
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V. CONCLUSION
The epigenetic inactivation of GPX3 is a frequent finding in OSCC progression and may 
be a crucial molecular mechanism in the pathogenesis of OSCC. Our findings provide 
further evidence for GPX3 as a diagnostic and prognostic biomarker in OSCC. GPX3 
may also serve as a possible therapeutic target in patients with OSCC. However, at 
present, little is known about the role of GPX3 in OSCC. In the future, further studies 
will be needed to investigate the molecular mechanisms underlying the role of GPX3 
inactivation in the pathogenesis and clinical assessment of OSCC.
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국문요약
구강편평세포암종에서 DNA hypermethylation에 의한 glutathione 
peroxidase 3 발현의 임상병리학적 의의
<지도교수 차 인 호>
연세대학교 대학원 치의학과
정 재 승
활성산소는 암유전자의 구조적 변화를 일으켜 암의 발생과 진행에 관련이 되
어있다. glutathione peroxidase 3(GPX3)는 glutathione family 중 하나이며 활성산소
를 제거하는 주요 항 산화 효소이다. 다양한 암에서 promoter hypermethylation
에 의한 GPX3 의 downregulation GPX3 의 tumor suppressor 로서의 가능성에 관한
많은 연구들이 있었다.
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본 연구의 목적은 구강편평세포암종에서 methylation 정도와 GPX3 발현에 관한
상관관계를 보고, 구강편평세포암종 환자에서 GPX3 발현정도가 임상병리학적
예후에 미치는 영향을 보고자 하였다.
GPX3 promoter hypermethylation 은 구강편평세포암종 세포주와 조직에서 모두
높은 빈도(100%, 75%)로 관찰되었으나 정상 구강 점막조직에서는 낮은 빈도
(33.3%)로 관찰되었다. 구강편평세포암종 세포주에서 demethylation agent 인 5-
Aza 처리 후 GPX3 발현이 복원되었고, GPX3 downregulation 과 methylation 은
연관성을 가지고 있음을 확인하였다. 모든 정상 구강점막조직에서 GPX3 
protein 발현이 관찰되었다. 반면에 구강편평세포암종 조직에서는 정상 구강점
막조직에 비하여 GPX3 protein 발현이 통계학적으로 유의한 감소를 보였다. 구
강편평세포암종 환자 군에서 GPX3 발현은 세포 분화도, 림프절 전이, 혈관침
습 및 누적 생존률에서 각각 통계학적 유의성을 보였다.
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결론적으로 promoter hypermethylation 에 의한 GPX3 downregulation 은 구강편평
세포암종 환자의 진단 및 예후를 보는 생체표지자로의 의미가 있다고 할 수
있겠다.
핵심되는 말 : GPX 3 downregulation , promoter hypermethylation , 생체표지자, 구강
편평세포암종
